Role of Serum Prolidase and Oxidative Stress Levels in Diabetic Neuropathy Patients
International Journal of Current Pharmaceutical Review and Research · 30.07.2026 · 18 (07)
DOI: 10.25258/ijcpr.18.7.80 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.07.2026. Verfasst von Rajendra Saran und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Diabetic neuropathy (DN) remains a highly disabling microvascular complication of diabetes mellitus. Chronic hyperglycemia prompts cellular damage through multiple metabolic routes, with oxidative stress serving as a primary driver of neuropathic structural degradation [1,2]. Concurrently, altered tissue remodelling and collagen degradation feature heavily in late-stage diabetic complications. Serum prolidase activity governs the final step of collagen degradation, yet its definitive role alongside systematic systemic oxidative stress parameters in DN remains poorly characterized [2,3]. This study evaluated the collective dynamics of serum prolidase activity, total oxidant status (TOS), total antioxidant status (TAS), and the oxidative stress index (OSI) in patients with diabetic neuropathy.
Methods
A cross-sectional, comparative observational study was conducted involving 80 participants recruited from MGM Medical College, Indore, MP. The subjects were classified into three distinct cohorts: diabetic neuropathy cases (n=40), diabetic controls without neuropathy (n=40), and non-diabetic healthy controls (n=40). Serum prolidase activity, TAS, and TOS were spectrophotometrically determined using validated automated colorimetric assays [4,5], and the OSI was computed as the ratio of TOS to TAS. Glycemic indices and lipid profiles were correlated with these markers using Pearson’s data analysis via SPSS Version 19.
Results
Serum TOS levels were markedly higher in DN patients (0.341 ± 0.187 μmol H2O2 Eq./L) compared to diabetic controls (0.258 ± 0.081 μmol H2O2 Eq./L) and non-diabetic controls (0.129 ± 0.041 μmol H2O2 Eq./L; p < 0.0001). The OSI similarly displayed a highly significant upward trend across the cohorts (1.301 ± 1.412 vs. 0.563 ± 0.311 vs. 0.402 ± 0.213; p < 0.0001). Serum prolidase activity was highest in the DN cohort (382.6 ± 138.5 U/L) compared to diabetic (368.4 ± 132.9 U/L) and healthy controls (361.2 ± 150.3 U/L), signaling active tissue remodeling. Prolidase activity demonstrated a significant negative correlation with HbA1c (r = -0.327, p = 0.039), high-density lipoprotein (HDL, r = 0.432, p = 0.004), and very low-density lipoprotein (VLDL, r = -0.315, p = 0.041).
Conclusion
Accelerated systemic oxidative stress, represented by distinct elevations in TOS and OSI, combined with altered serum prolidase dynamics, highlights a combined pathophysiological framework of oxidative damage and aberrant collagen turnover in diabetic neuropathy. These parameters serve as potential biomarkers for microvascular deterioration in diabetic patients.
Zitieren
APA
Saran, R., Lohokare, R., Manyal, R., & Sarkar, P. D. (2026). Role of Serum Prolidase and Oxidative Stress Levels in Diabetic Neuropathy Patients. International Journal of Current Pharmaceutical Review and Research, 18(07). https://doi.org/10.25258/ijcpr.18.7.80
Vancouver
Saran R, Lohokare R, Manyal R, Sarkar PD. Role of Serum Prolidase and Oxidative Stress Levels in Diabetic Neuropathy Patients. International Journal of Current Pharmaceutical Review and Research. 2026;18(07). doi:10.25258/ijcpr.18.7.80
BibTeX
@article{Saran2026,
author = {Saran, Rajendra and Lohokare, Rajeev and Manyal, Rohit and Sarkar, Purnima Dey},
title = {Role of Serum Prolidase and Oxidative Stress Levels in Diabetic Neuropathy Patients},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {07},
doi = {10.25258/ijcpr.18.7.80}
}
EUVIMED